News Could Alzheimer's be predicted with a finger-prick test? An international trial has started to see if a simple finger-prick blood test could predict Alzheimer's before symptoms start.
News Rumour confirmed as Lilly buys Ventyx for $1.2 billion Eli Lilly has agreed a $1.2bn takeover of Ventyx Bio and its clinical-stage drugs for inflammatory and cardiometabolic diseases.
News AC Immune says Parkinson's drug slows progression AC Immune's active immunotherapy study backs up the alpha-synuclein hypothesis in Parkinson's disease, after disappointments in earlier trials.
News FDA clears trial of 'vectorised' ALS antibody from VectorY VectorY has been cleared by the FDA to start human trials of a drug against a target implicated in up to 97% of amyotrophic lateral sclerosis cases.
R&D Unlocking the future of neurodegeneration research: How auto... On the emergence of brain organoids and the advent of automation, the latter being essential for high-throughput approaches drug development demands.
News Alector ditches GSK-partnered dementia drug and cuts staff Alector has abandoned latozinemab as a treatment for frontotemporal dementia, four years after GSK licensed the antibody in a $700m upfront deal.
News Kidney biotech R1's $78m debut, and other biofinancings Biofinancing values have tailed off a bit after a strong start to 2026, but March has seen $50m+ rounds for R1, Crossbow, Excalipoint, and Prolium.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
